Dr. Peterson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
711 Medical Village Dr
Edgewood, KY 41017Phone+1 859-287-3045Fax+1 859-578-3800
Education & Training
- Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2016 - 2019
- Duke University HospitalResidency, Internal Medicine, 2013 - 2016
- University of Rochester School of Medicine and DentistryClass of 2013
Certifications & Licensure
- IN State Medical License 2022 - 2025
- KY State Medical License 2022 - 2025
- MA State Medical License 2016 - 2023
- RI State Medical License 2021 - 2022
- NC State Medical License 2013 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
Publications & Presentations
PubMed
- 35 citationsReduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.Benjamin E Peterson, Deepak L. Bhatt, Ph. Gabriel Steg, Michael Miller, Eliot A. Brinton
Circulation. 2021-01-05 - 138 citations2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percuta...Dharam J. Kumbhani, Christopher P. Cannon, Craig J. Beavers, Deepak L. Bhatt, Adam Cuker
Journal of the American College of Cardiology. 2021-02-09 - 11 citationsPrognostic significance of heart rate variability among patients treated with cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implant...Saadia Sherazi, Valentina Kutyifa, Scott McNitt, Mehmet K. Aktas, Jean-Philippe Couderc
JACC. Clinical Electrophysiology. 2015-03-01
Press Mentions
- Addition of Icosapent Ethyl Cuts CV Risk in Patients with Prior PCIMarch 24th, 2022
- Amarin’s Vascepa Shows Lower Risk of Fatal CV Events in REDUCE-IT Prior PCI Post Hoc SubanalysisMarch 10th, 2022
- REDUCE-IT: Significant Reduction in Coronary Revascularizations with Icosapent EthylMay 15th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: